DENVER, Colo. (247MarketNews) — The 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, November 13-15, is bringing together an unusually broad group of biotechnology companies pursuing new approaches to some of the most difficult-to-treat brain cancers. Among the participants are NeOnc Technologies Holdings (NASDAQ:NTHI), Nuvation Bio (NYSE:NUVB), Jazz Pharmaceuticals (NASDAQ:JAZZ), Cerenome (NASDAQ:CNSY), BioLineRx (NASDAQ:BLRX), Alpha Tau Medical (NASDAQ:DRTS), and privately held Diakonos Oncology. Their programs range from targeted drugs and immunotherapy to localized radiation and experimental drug-delivery technologies.

The significance of this year's meeting extends beyond the number of presentations. Several companies are bringing updated human clinical data, while others are highlighting Phase 1 and Phase 2 development progress, new trial designs or expanded enrollment. For interested parties, the important distinction is which programs are producing meaningful clinical evidence, which are still primarily supported by preclinical research, and which have identifiable regulatory or financing milestones ahead.

NeOnc: Two clinical programs and FDA meetings put spotlight on NEO100 and NEO212

NeOnc (NASDAQ: NTHI) is bringing two distinct investigational brain cancer therapies to SNO at a time when its regulatory outlook is becoming increasingly important. Its first presentation covers updated Phase 1/2a and compassionate-use experience with intranasal NEO100 in recurrent IDH1-mutant grade III/IV astrocytoma. The second examines oral NEO212, a temozolomide-perillyl alcohol conjugate, with Phase 1 safety, pharmacokinetic and early activity findings in recurrent glioblastoma and brain metastases. The two programs offer different approaches to treating central nervous system cancers, giving NeOnc more than one potential clinical-development opportunity.

The previous NEO100 Phase 2a results included six-month progression-free survival of 48.9%, compared with a historical benchmark of 20%, and median overall survival of 26.09 months, according to the company. NeOnc is preparing for a January 2027 FDA Type B meeting to discuss a potential accelerated approval pathway and proposed Phase 3 design. NEO212 also has an upcoming November 23 FDA meeting. Investors will be watching whether the new presentations strengthen the clinical rationale for both programs and help establish a fast-track regulatory strategy.

Cerenome: REYOBIQ data and commercial diagnostics update create second catalyst

Cerenome(NASDAQ: CNSY) is approaching SNO with a combination of therapeutic and diagnostic developments. Its lead investigational therapy, REYOBIQ (rhenium-186 obisbemeda), is being evaluated in leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers. The SNO presentation focuses on the ReSPECT-LM program, including pharmacokinetic and pharmacodynamic assessments and emerging information from repeated dosing. This is an important area of investigation because leptomeningeal metastases involve cancer spreading into the membranes and cerebrospinal fluid surrounding the brain and spinal cord, where treatment options remain limited.

Cerenome also scheduled a November 16 conference call to discuss the SNO findings, provide an update on its CNSide diagnostic business and report third-quarter financial results. This creates an opportunity for investors to evaluate both the therapeutic pipeline and the commercial foundation supporting the company. CNSide is designed to analyze cerebrospinal fluid for cellular and molecular evidence of cancers involving the central nervous system.

Nuvation Bio: safusidenib results could strengthen targeted treatment opportunity

Nuvation Bio (NYSE: NUVB) is using SNO to expand the clinical picture for safusidenib, its investigational selective inhibitor of mutant IDH1. The company announced four presentations, including updated long-term Phase 2 J201 results in chemotherapy- and radiotherapy-naive patients with Grade 2 IDH1-mutant glioma. Three additional presentations cover ongoing studies, including the Phase 3 SIGMA program. The updated J201 poster is particularly relevant because it includes additional information beyond the topline results announced in July.

The opportunity is significant because IDH1-mutant gliomas can affect relatively young adults who may live with the disease for many years, creating a need for treatments that can provide durable disease control without unacceptable toxicity. Safusidenib is being developed as a targeted approach to this molecularly defined population.

Jazz: Phase 3 progress puts dordaviprone at the center of rare brain cancer research

Jazz Pharmaceuticals (NASDAQ: JAZZ) brings a considerably more advanced development program to SNO through dordaviprone, marketed in the United States as Modeyso. Formerly known as ONC201, the therapy is being evaluated in the Phase 3 ACTION trial in patients with newly diagnosed H3 K27M-mutant diffuse glioma who have completed frontline radiation therapy. The randomized study compares placebo with once-weekly and twice-weekly dosing, with overall survival as its primary endpoint. Jazz is also presenting research involving ONC206, now known as JZP3507, in recurrent grade 2 or 3 meningioma.

Jazz's presentations illustrate how the field is moving beyond early experimental research toward larger confirmatory studies in genetically defined brain cancer populations. Dordaviprone already has a U.S. regulatory and commercial history in H3 K27M-mutant diffuse midline glioma, making the ACTION study important to its potential expansion into an earlier treatment setting. Investors should watch for evidence that the Phase 3 program can establish a meaningful survival benefit and clarify the appropriate dosing strategy. The company's broader research portfolio also provides additional exposure to rare brain tumors beyond glioblastoma.

BioLineRx and Hemispherian: GLIX1 advances from preclinical promise toward human testing

BioLineRx (NASDAQ: BLRX) and its private Norwegian partner Hemispherian are developing GLIX1, an investigational oral small molecule designed to activate TET2 and interfere with cancer-cell DNA repair mechanisms. The companies announced two GLIX1 presentations at SNO, covering preclinical research and the design of its Phase 1/2a clinical study in recurrent or progressive high-grade glioma. Earlier research presented at the European Association of Neuro-Oncology meeting reported activity in multiple glioblastoma animal models, including a temozolomide-resistant patient-derived model. The companies also reported that GLIX1 achieved brain exposure in mice at 68% to 85% of plasma levels.

The Phase 1/2a study, initiated in 2026, is designed to evaluate safety, tolerability, pharmacokinetics and early antitumor activity, with dose escalation guiding the selection of a recommended Phase 2 dose. GLIX1 is potentially interesting because it is being investigated against a biological mechanism different from conventional chemotherapy.

Alpha Tau Medical: New REGAIN findings could provide an important look at localized radiation for recurrent glioblastoma

Alpha Tau Medical (NASDAQ: DRTS) is bringing a different technological approach to the glioblastoma treatment landscape with Alpha DaRT, a localized alpha-radiation therapy designed to destroy tumor tissue while limiting radiation exposure to surrounding healthy tissue. Its REGAIN study is evaluating the technology in patients with recurrent glioblastoma who are not candidates for surgical resection and have previously received central nervous system radiation. The FDA has allowed the U.S. study to expand to as many as 20 patients, with feasibility and safety serving as the primary objectives.

Alpha Tau also scheduled a November 16 investor call to review new interim REGAIN findings with the principal investigator and company leadership. Investors will want to understand the number of patients treated, treatment-related adverse events, technical feasibility and any early evidence of tumor response or disease control.

Diakonos Oncology: Bringing a potentially differentiated dendritic-cell immunotherapy to glioblastoma race

Diakonos Oncology’s DOC1021 program deserves attention alongside the listed companies because it is bringing clinical experience in both newly diagnosed and recurrent glioblastoma to SNO. DOC1021, also known as dubodencel, is a patient-derived, double-loaded dendritic-cell therapy that combines a patient's dendritic cells with tumor lysate and amplified tumor-derived messenger RNA prepared from that patient's tumor specimen. The objective is to stimulate an immune response against tumor-specific targets rather than relying exclusively on conventional chemotherapy or radiation.

Diakonos has selected its Phase 1 and Expanded Access Protocol experience for a rapid oral presentation and poster, while also introducing its ongoing Phase 2 study in newly diagnosed glioblastoma. The company reports that DOC1021 has received FDA Fast Track designation for glioblastoma, pancreatic cancer and unresectable or metastatic cutaneous melanoma, as well as Orphan Drug designation for glioblastoma.

About 247MarketNews

In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.